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BACKGROUND: The Norwegian Breast Cancer Screening Program started in 1996. To the authors’ knowledge, this is the first report
using individual-based data on invitation and participation to analyze breast cancer mortality among screened and nonscreened
women in the program. METHODS: Information on dates of invitation, attendance, breast cancer diagnosis, emigration, death, and
cause of death was linked by using unique 11-digit personal identification numbers assigned all inhabitants of Norway at birth or immi-
gration. In total, 699,628 women ages 50 to 69 years without prior a diagnosis of breast cancer were invited to the program from
1996 to 2009 and were followed for breast cancer through 2009 and death through 2010. Incidence-based breast cancer mortality
rate ratios (MRRs) were compared between the screened and nonscreened cohorts using a Poisson regression model. The MRRs were
adjusted for calendar period, attained age, years since inclusion in the cohorts, and self-selection bias. RESULTS: The crude breast
cancer mortality rate was 20.7 per 100,000 women-years for the screened cohort compared with 39.7 per 100,000 women-years for
the nonscreened cohort, resulting in an MRR of 0.52 (95% confidence interval, 0.47-0.59). The mortality reduction associated with
attendance in the program was 43% (MRR, 0.57; 95% confidence interval, 0.51-0.64) after adjusting for calendar period, attained age,
years after inclusion in the cohort, and self-selection bias. CONCLUSIONS: After 15 years of follow-up, a 43% reduction in mortality
was observed among women who attended the national mammographic screening program in Norway. Cancer 2013;119:3106-12. VC
2013 American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial
License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used
for commercial purposes.
KEYWORDS: mammography; mass screening; female; breast neoplasms=mortality; breast neoplasms=prevention and control; breast
neoplasms=radiography; Norway=epidemiology.
INTRODUCTION
The objective of mammographic screening is to detect breast cancer at an early stage and thereby reduce mortality from
the disease. A beneficial effect from such screening was observed in several randomized controlled trials1-3 and most
recently in the analyzes of the European service screening programs4,5 and in a review by an independent panel in the
United Kingdom of the benefits and harms of breast cancer screening.3
The extent of mortality reduction after the implementation of organized service screening has been debated for deca-
des.1,2,6 Some issues that have been discussed are the study design, the estimation methods, the required length of follow-
up, and the effects of changes in treatment over time.7-12
The Euroscreen Working Group estimated a 25% reduction in breast cancer mortality in cohort studies and a 31%
reduction in case-control studies among women who were invited versus noninvited to service screening programs,4
whereas the UK independent panel reported a reduction in breast cancer mortality of 20%, based on randomized con-
trolled trials.3 Two previous studies used individual cancer data but aggregated screening data to address the effect of the
Norwegian Breast Cancer Screening Program (NBCSP) among women who were invited to the program.9,13 Those stud-
ies reported 10% and 11% reductions in breast cancer mortality associated with being invited to screening. The use of
aggregated screening data and short follow-up may explain the low estimates in the 2 studies.
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To take advantage of the individual level data on in-
vitation and screening history, we used a cohort study
design and an incidence-based approach to analyze breast
cancer mortality among women who were invited to the
screening program in Norway. This is the first mortality
analysis from the program using these individual level
screening data. We specifically tested the effect of attend-
ing the program on breast cancer mortality after adjusting
for calendar period, attained age, time since inclusion in
the cohort, and self-selection bias.
MATERIALS AND METHODS
Methods
The NBCSP is administered by the Cancer Registry of
Norway and targets women ages 50 to 69 years.14 The
program started in 4 of 19 counties in 1996 and became
nationwide in 2005. The program is run according to Eu-
ropean guidelines.15 Each woman in the target group
receives a personal letter inviting her to undergo 2-view
mammography screening every second year, regardless of
her cancer history (Fig. 1).
Cancer reporting is mandatory by law in Norway,
and the Cancer Registry has registered cancers since
1953.16 The database is 99% complete for solid tumors,
including breast cancer.17 Vital status, date of emigration,
and date and cause of death are available from Statistics
Norway. This information is regularly linked to the Can-
cer Registry data by the unique 11-digit personal identifi-
cation number assigned to all residents of Norway.
We received an anonymized file with individual level
dates of invitations and attendance for all women who
were invited to the NBCSP and linked this information to
the dates of diagnosis of breast cancer, emigration, and
death (Fig. 1). The database was created in November
2011. No ethical committee approval was necessary,
because we received anonymized data only.
Women were eligible for inclusion if they had been
invited to the program during the period from 1996 to
2009. Women who were diagnosed with breast cancer
before the postal date of the invitation to the program
were excluded (Fig. 1). No organized preliminary clinical
breast examination or mammogram screening was per-
formed before the invitation to eliminate prevalence can-
cers from the population before attendance in the
NBCSP. Women were followed until emigration, death,
or the end of follow-up (December 31, 2010), whichever
Figure 1. The number of women invited and screened in the Norwegian Breast Cancer Screening Program from 1996 to 2009,
exclusions, and final study cohorts, including women-years, the number of breast cancer cases, and the number of breast cancer
deaths from 1996 to 2010. DCIS indicates ductal carcinoma in situ.
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date came first. Women who were invited to the NBCSP
were defined as screened or nonscreened based on the date
of their first attendance in the program. A woman con-
tributed with women-years in the nonscreened cohort
from the postal date of her first invitation to the date of
her first screening attendance (or, for women who were
diagnosed with cancer, until the end of follow-up),
whereas a woman contributed with women-years in the
screened cohort from the date of her first screening
attendance to the end of follow-up. Only women who
were free from breast cancer could change their status
from nonscreened to screened.
We used a never=ever screened approach in which
the women were considered ever screened after their first
screening attendance. The International Classification of
Diseases, Ninth Revision (ICD-9)=ICD-10 definition of
breast cancer was used as the underlying cause of death.18
In Norway, cause of death is reported in 3 levels: immedi-
ate, intermediate, and the underlying cause of death is
reported.19 To correct for errors and irrational conclu-
sions drawn by the physician, rules from the World
Health Organization are used to ensure correct classifica-
tion on the basis of the death certificate. Until 2005, the
underlying cause of death was determined manually; how-
ever, since 2005, the underlying cause of death has been
determined electronically. The electronic version requires
that the cause of death must fit into ICD-10 codes.19
Statistics
We used Poisson regression to estimate the mortality rate
ratio (MRR) of breast cancer death among women who
attended in the program compared with those who did not
attend. We adjusted for calendar period (continuous),
attained age (continuous), and years since inclusion in the
screened and nonscreened cohort (in 3-year categories).
Using a categorical variable for calendar period and includ-
ing county of residence in the model altered the MRR to
0.5%. Thus, we retained the continuous variable for cal-
endar period and did not include county in the model.
Screened women are expected to have lower breast can-
cer mortality than those who do not attend screening simply
because those who let themselves be screened are more con-
scious about their health or lifestyle.20,21 We adjusted for
this self-selection bias using the following formula provided
by Duffy et al20:W05W (pD=[12 (12 p)D]), whereW0 is
the parameter of interest (ie, the estimated MRR of breast
cancer death adjusted for selection bias), p is the proportion
of women complying with the invitation to screening; W is
the estimatedMRR of breast cancer death for compliers ver-
sus noncompliers; and D is the MRR of breast cancer death
for noncompliers compared with uninvited women.20
In our study, p was used to indicate the percentage of
ever-screened women from 1996 to 2009, and W was the
adjusted MRR for screened compared with nonscreened
women, as indicated in Table 1. Because this study only
included invited women, the MRR of breast cancer death
for noncompliers compared with uninvited women (D)
was not available. Therefore, we used the average estimate
of 1.36 with a 95% confidence interval (CI) of 1.11 to
1.67, from the article by Duffy and colleagues.20 The Stata
statistical software package (version 12.1; Stata Corpora-
tion, Station, Tex) was used for the analyses. We used 2-
sided P values and a statistical significance level of .05.
RESULTS
From 1996 to 2009, 699,628 women with no history of
breast cancer received at least 1 invitation to the screening
program in Norway, and 588,982 attended once or more,
TABLE 1. Number of Invasive Breast Cancer Cases, Number of Breast Cancer Deaths, Follow-Up in Women-
Years, Crude Breast Cancer Mortality Rates, and Adjusted Breast Cancer Mortality Rate Ratios Associated
With Screening in the Norwegian Breast Cancer Screening Program, 1996-2010
Cohort
No. of Invasive
Breast Cancer
Casess
No. of Breast
Cancer Deaths
Follow-Up,
Women-Years
Crude Breast
Cancer Mortality
Rate (95% CI),
31025
MRR (95% CI)
Crude Breast
Cancer
Mortality
Adjusted Breast
Cancer
Mortalitya
Adjusted for
Self-Selection
Bias: Breast
Cancer Mortalityb
Nonscreened 2055 392 988,641 39.7 (35.8-43.8) 1.00 1.00 1.00
Screened 13,162 998 4,814,060 20.7 (19.5-22.1) 0.52 (0.47-0.59) 0.39 (0.35-0.44) 0.57 (0.51-0.64)
Abbreviations: CI, confidence interval; MRR, mortality rate ratio.
a Poisson regression was adjusted for calendar period (continuous), attained age (continuous), and time since inclusion in the group (categorical; 3-year
groups).
b Poisson regression was adjusted for self-selection bias (see Materials and Methods) and for calendar period (continuous), attained age (continuous), and
time since inclusion in the group (categorical; 3-year groups).
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resulting in a compliance rate of 84%. The average time
in the screened and nonscreened cohorts for the women
who were diagnosed with cancer was 9.7 years (median,
9.3 years) and 8.6 years (median, 8.2 years), respectively.
The average time from diagnosis of breast cancer to the
end of follow-up was 5.7 years (median, 5.1 years) for
screened women and 5.1 years (median, 4.5 years) for
nonscreened women.
Crude breast cancer mortality rates were 20.7 and
39.7 per 100 000 women-years in the screened and
nonscreened cohorts, respectively, which resulted in a
crude MRR of 0.52 (95% CI, 0.47-0.59) (Table 1). A
statistically significant increase in MRR was observed
according to attained age and years since inclusion in the
cohorts, but not according to calendar period (results not
shown). The MRR was 0.39 (95% CI, 0.35-0.44) when
adjusted for calendar period, attained age, and years since
inclusion in the cohorts (Table 1). After adjustment for
self-selection bias, we obtained an MRR of 0.57 (95% CI,
0.51-0.64). An MRR of 0.75 (95% CI, 0.67-0.84) was
achieved using the more conservative upper 95% CI value
for D of 1.67 from Duffy et al,20 whereas using the lower
95% CI value for D of 1.11 resulted in an MRR of 0.44
(95% CI, 0.39-0.49). The difference in crude mortality
rates between the 2 cohorts tended to increase with time
since inclusion in the cohorts and reached a statistically
significant difference after 2 years (Table 2; Figs. 2,3).
DISCUSSION
This is the first mortality analysis of the national screening
program in Norway using individual level screening data.
Fifteen years after the start of the program, the screened
cohort had a 43% lower breast cancer mortality rate com-
pared with the nonscreened cohort. These results are con-
cordant with studies in other service screening programs
and with the analyses from the Euroscreen review, which
reported reductions from 38% to 48% in breast cancer
mortality among screened women compared with
nonscreened women.4,5
We observed a lower mortality rate in the screened
cohort versus the nonscreened cohort as early as the second
year after inclusion in the cohorts (Table 2). Data from
randomized controlled trials have indicated that cumulative
breast cancer mortality rates start diverging 4 years after
randomization,22 but it has been argued (most recently by
the independent UK panel) that at least 10 years of follow-
up are needed to observe maximum effect.3 Because our
findings were based on a service screening program with no
randomization, self-selection bias may explain the division
of the curves as early as 2 years after randomization. Such
self-selection bias is caused by the underlying differences
between attendees and nonattendees to the screening pro-
gram that would also be present in the absence of screening.
Women who attend a screening program are expected to
have a lower risk of breast cancer death compared with
TABLE 2. Number of Women-Years, Number of Breast Cancer Deaths, Crude Breast Cancer Mortality Rates,
and Crude Cumulative Breast Cancer Mortality Rate per 100,000 Women-Years by Time Since Inclusion in
the Screened and Nonscreened Cohorts of the Norwegian Breast Cancer Screening Program, 1996-2010
Years Since
Inclusion in
the Cohorts
Screened Cohort Nonscreened Cohort
Women-
Years
No. of
Breast
Cancer
Deaths
Crude Breast
Cancer Mortality
Rate per 100,000
Women-Years
(95% CI)
Crude Cumulative
Breast Cancer
Mortality Rate
per 100,000
Women-Years
(95% CI)
Women-
Years
No. of
Breast
Cancer
Deaths
Crude Breast
Cancer Mortality
Rate per 100,000
Women-Years
(95% CI)
Crude Cumulative
Breast Cancer
Mortality
Rate per 100,000
Women-Years
(95% CI)
1 588,149 13 2.2 (1.2-3.8) 2.2 (1.0-3.4) 348,270 15 4.3 (2.4-7.1) 4.3 (2.1-6.5)
2 573,665 27 4.7 (3.1-6.9) 6.9 (3.9-9.9) 102,719 20 19.5 (11.9-30.1) 23.8 (13.1-34.5)
3 543,231 45 8.3 (6.0-11.1) 15.2 (9.8-20.6) 91,511 29 31.7 (21.2-45.5) 55.5 (33.2-77.7)
4 512,175 83 16.2 (16.2-16.2) 31.4 (22.5-40.3) 82,104 41 49.9 (35.8-67.7) 105.4 (67.9-142.9)
5 480,485 112 23.3 (19.2-28.1) 54.7 (41.5-67.9) 74,635 48 64.3 (47.2-85.7) 169.7 (114.0-225.5)
6 443,308 99 22.4 (18.2-27.2) 77.0 (59.5-94.7) 67,546 38 56.3 (39.8-77.2) 226.0 (152.3-299.6)
7 393,838 114 28.9 (23.9-34.8) 106.0 (83.1-128.9) 58,064 35 60.3 (42.0-83.8) 286.3 (192.7-379.8)
8 336,342 100 29.7 (24.2-36.2) 135.7 (107.0-164.5) 46,491 39 83.9 (59.7-114.7) 370.1 (250.2-490.0)
9 259,792 88 33.9 (27.2-41.7) 169.6 (133.8-205.4) 33,798 36 106.5 (74.6-147.5) 476.7 (321.9-631.4)
10 194,721 77 39.5 (31.2-49.4) 209.1 (164.5-253.8) 24,162 28 115.9 (77.0-167.5) 592.5 (394.9-790.2)
11 154,740 49 31.7 (23.4-41.9) 240.8 (187.3-294.3) 18,927 16 84.5 (48.3-137.3) 677.1 (438.0-916.1)
12 129,748 73 56.3 (44.1-70.4) 297.1 (230.7-363.5) 15,598 20 128.2 (78.3-198.0) 805.3 (510.0-1100.6)
13 114,605 56 48.9 (36.9-64.5) 345.9 (266.7-425.2) 13,747 17 123.7 (72.0-198.0) 929.0 (574.9-1280.3)
14 70,636 41 58.0 (41.7-78.7) 404.0 (307.0-501.0) 8803 7 79.5 (32.0-163.8) 1008.5 (595.5-1421.2)
15 18,626 21 112.7 (69.8-172.3) 516.7 (371.5-661.9) 2265 3 132.5 (27.3-387.1) 1140.9 (578.1-1703.7)
Abbreviations: CI, confidence interval.
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nonattendees because of personal characteristics, such as
health awareness, family history of breast cancer, and use of
mammography before the screening program.20,21
To adjust for self-selection bias, we used the model
described by Duffy et al.20 Using the value D (the MRR
of breast cancer death in noncompliers [nonscreened]
Figure 3. Crude cumulative breast cancer mortality rates are illustrated for the screened and nonscreened cohorts of women
who were invited to the Norwegian Breast Cancer Screening Program according to the time since inclusion in the cohorts from
1996 to 2010.
Figure 2. Crude breast cancer mortality rates are illustrated for the screened and nonscreened cohorts of women who were
invited to the Norwegian Breast Cancer Screening Program according to the time since inclusion in the cohorts from 1996 to
2010.
Original Article
3110 Cancer September 1, 2013
compared with the noninvited) from that publication
may be considered a limitation of our study, because that
value was based on randomized controlled trials and was
not from the NBCSP.23 Our estimate of the screening
effect may be overestimated if D is larger in the NBCSP
than in the randomized controlled trials, and vice versa.
However, other European service screening programs
have reported values for D of 1.11 and 1.17,24,25 which
are similar to the lower level of the 95% CI for D used in
our study. However, even if we used a value of 1.67 forD,
the upper value of the 95% CI for D in our adjustment
for self-selection bias, which we believe is unreasonably
high for Norway; the mortality reduction is still 25% in
favor of screening. We did not estimateD in our own data
because we did not have access to individual level data on
women who were not invited to the program.
The objective of our study was to estimate the mor-
tality reduction in women who were screened in the
NBCSP, and not the effect of mammography in Norwe-
gian women in general. Use of mammography outside the
program, both among nonscreened women and in
between 2 screening rounds among screened women,
could have reduced the estimated mortality reduction in
our study. In Norway, 38% of the prevalently screened
women during the period from 1996 to 2006 reportedly
had received a mammogram within the last 3 years,
whereas 64% reported ever use of mammography before
attending the program (results not shown). Furthermore,
a recently published study from 1 of the 19 counties in
Norway indicated that 32% of the cancers detected in
invited, nonattending women were asymptomatic.26 The
mortality reductions would likely have been even greater
in our study if data on such private screening had been
available, so that a comparison could have been made
between women who participated in the NBCSP and
women who were never screened, either privately or as
part of the NBCSP.
Breast cancer treatment improved after the start-up
of the NBCSP because of the contemporary establishment
of breast clinics.12 However, this should not to have bi-
ased the estimates in our study, because only women who
were invited to the program were included. Furthermore,
socialized medicine and nationwide guidelines for breast
cancer treatment27 increase the probability, but do not
guarantee, that women throughout the country receive
similar treatment. Although we cannot completely
exclude the possibility that the screened women received
better treatment than nonscreened women, we believe this
is unlikely. It is also unlikely that such a bias would have
caused the divergence of MRRs over time.
It can be argued that, to assess the effect of a screen-
ing program on a population level, breast cancer mortality
in invited women should be compared with that of nonin-
vited women. Two previous studies estimated reductions
in breast cancer mortality of 10% and 11% for NBCSP-
invited women versus noninvited women.9,13 Those stud-
ies were limited by a lack of individual screening data and
short follow-up and, thus, probably underestimated the
true effect of screening on mortality.
To correctly evaluate the effectiveness of the
NBCSP, individual level data on never-invited women
would be needed. Such information is currently not avail-
able. Because we had access to individual level data on
women who were invited to the NBCSP, we focused on
mortality in ever-screened women versus never-screened
women. However, the mortality reduction on a popula-
tion level corresponds to the efficacy (mortality reduction
in screened vs nonscreened women) multiplied by the
compliance rate.28,29 By using our estimate for mortality
reduction (43%) and a compliance rate of 84%, our esti-
mate of the mortality reduction on the population level is
36% (43%3 84%) in favor of the invited women.
The average follow-up for the screened cohort was
substantially longer than that for the nonscreened cohort
(Table 1). This was because >70% of the women who
attended the screening program did so within 2 weeks of
the first invitation.30 However, our model included
adjustments for time since inclusion in the cohorts.
Our observational cohort study has several strengths.
We used individual level data on invitation and attend-
ance in the program as well as on the outcome of the
screening examination. The Cancer Registry of Norway is
essentially complete in terms of breast cancer reporting.17
In conclusion, the results from this first mortality analysis
based on individual level data from the NBCSP, in which
women ages 50 to 69 years were invited to biennial screen-
ing, indicate a substantial reduction in mortality from
breast cancer in screened women compared with
nonscreened women.
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